What is ONC's market cap?

$47.51B, based on the Nov 12 close of $415.96.

What is ONC's P/E ratio?

51.9× trailing-twelve-month earnings of $915.57M.

What sector is ONC in?

Healthcare, in the Pharmaceuticals industry.

NASDAQ · ONCHealthcarePharmaceuticals

BeOne Medicines Ltd. American Depositary Shares (ONC)

$415.96−0.96%

Close Nov 12, 2026 · split-adjusted

Nov 12, 2026$415.96▲ 10.20% in range

Nov 12, 2025Low $260.27 · High $424.00Nov 12, 2026

What changed · written from our data

As of Nov 12, 2026

BeOne Medicines Ltd. American Depositary Shares closed at $415.96 on Nov 12, down 0.96%, 1.9% below its 52-week closing high. Volume of 342.7K shares was 0.70× its 20-day average (below normal).

Split-adjusted performance: +18.3% over one month, +36.6% over six months, +21.0% over one year.

In the quarter ended Sep 30, 2026, revenue was $1.89B, up 33.8% from a year earlier, with a net margin of 20.4%.

Short interest was 1.6M shares at the Oct 30 settlement, down 10.6% from the prior report (4.4 days to cover).

Market cap$47.51B114.2M shares

Revenue · quarter$1.89B+33.8% YoY

Diluted EPS$0.25+212.5% YoY

P/E · TTM51.9×P/S 7.2×

Net margin20.4%Gross 88.5%

Dividend yieldNone

52-week range260.27 – 424.00−1.9% from high

Volume342.7K0.70× 20-day avg

Volatility · 60d32.0%Annualised

Short % of float—4.4 days to cover

Net cash$4.71BCash $5.78B

Next earnings—Not scheduled

Split-adjusted performance

1W +7.4%1M +18.3%3M +19.7%6M +36.6%YTD +36.9%1Y +21.0%3Y —5Y —

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 417 companies (100 = best)

6-month momentum—

Revenue growth—

Net margin—

Value (low P/E)—

Size—

Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.

Short interest

Details →

Shares short1.6M−10.6% vs prior

Days to cover4.4Settled Oct 30

% of float—

Short vol. 10d53.0%of daily volume

Closest peers by size in Pharmaceuticals

Company	Price	Today	6M	Rev. growth	Net margin	P/E	Mkt cap
ONCBeOne Medicines	$415.96	−0.96%	+36.6%	+33.8%	20.4%	51.9	$47.51B
ZLABZai Lab Limited	$26.04	−1.44%	+28.1%	−6.8%	−42.6%	—	$3.22B	Compare
GPCRStructure Therapeutics	$19.84	−5.30%	−50.2%	—	—	—	$1.41B	Compare
CMPSCOMPASS Pathways Plc American Depository Shares	$9.12	−1.94%	−14.1%	—	—	—	$1.29B	Compare
SLNSilence Therapeutics Plc American Depository Share	$19.80	+0.15%	+177.7%	—	—	—	$1.23B	Compare
AMRNAmarin	$11.67	−0.34%	−21.0%	−20.4%	0.6%	—	$490.6M	Compare
BCYCBicycle Therapeutics	$3.45	−6.50%	−26.1%	+190.2%	−30.8%	—	$241.8M	Compare
KZIAKazia Therapeutics Limited	$6.95	−6.46%	−49.7%	—	—	—	$108.1M	Compare
MREOMereo BioPharma Group	$0.3050	−0.52%	+24.0%	—	—	—	$48.7M	Compare

News about BeOne Medicines

All news →

All You Need to Know About BeOne Medicines Ltd. - Sponsored ADR (ONC) Rating Upgrade to Strong BuyZacks Investment Research · Oct 15, 2026▲ Positive

Quick answers

What does BeOne Medicines Ltd. American Depositary Shares do?: Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia.
What is ONC's market cap?: $47.51B, based on the Nov 12 close of $415.96.
What is ONC's P/E ratio?: 51.9× trailing-twelve-month earnings of $915.57M.
What sector is ONC in?: Healthcare, in the Pharmaceuticals industry.

About BeOne Medicines

Formerly known as BeiGene and founded in 2010 in Beijing, BeOne is a commercial-stage biotech firm that produces oncology therapeutics. The company's main product is Brukinsa, which is a small-molecule drug that treats multiple forms of non-Hodgkin lymphoma and leukemia. The company conducts drug discovery, runs global clinical trials, and manufactures drugs independently. As of 2025, Brukinsa made up 74% of total revenue, while it has two other approved commercialized drugs in its portfolio, Beqalzi and Tevimbra. While Brukinsa has global leadership, the other two drugs generate revenue mostly from China. Based on Brukinsa, BeOne competes mainly with AbbVie and AstraZeneca. The company also has more than 50 drugs in clinical trials in its active pipeline, focused on other cancers.

HQ: Basel, 12,000 employeesListed Feb 3, 2016beonemedicines.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology